Author + information
- Andreas Goette,
- Winghan Kwong,
- Michael Ezekowitz,
- Maciej Banach,
- Soren Hjortshoj,
- Dmitry Zamoryakhin and
- Gregory Lip
Background: ENSURE-AF (NCT 02072434) study, a multi-center, PROBE trial comparing edoxaban with enoxaparin/warfarin followed by warfarin alone in 2,199 non-valvular atrial fibrillation patients undergoing electrical cardioversion showed comparable rates of bleeding and thromboembolism between treatments. This subanalysis investigated the impact of therapy on treatment satisfaction and utilization of health care services.
Methods: The Perception of Anticoagulant Treatment Questionnaire (PACT-Q2) was completed by study subjects on day 28 post-cardioversion. Higher scores represent greater satisfaction. Health care resource utilizations were collected from randomization to day 28 post-cardioversion. Data from subjects who received at least one dose of study drugs were analyzed.
Results: Subjects treated with edoxaban were more satisfied than enoxaparin/warfarin in both PACT-Q treatment satisfaction and convenience scores. Difference in treatment satisfaction scores was greater in subjects who underwent non-transesophageal echocardiography (TEE)-guided cardioversion than in subjects who underwent TEE guided cardioversion. Edoxaban was associated with fewer clinical visits and fewer hospital days. However, rates of hospitalizations and emergency room visits were not different (table).
Conclusions: The convenience of edoxaban therapy over warfarin in patients undergoing cardioversion may provide greater treatment satisfaction and cost-savings to the health care system.
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Atrial Fibrillation and VT: Specific Situations and Newer Outcome Measures
Abstract Category: 8. Arrhythmias and Clinical EP: Supraventricular/Ventricular Arrhythmias
Presentation Number: 1190-102
- 2017 American College of Cardiology Foundation